DUR-928 / Durect 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   59 News 
  • ||||||||||  DUR-928 / Durect
    Review, Journal:  Larsucosterol: Endogenous Epigenetic Regulator for Treating Chronic & Acute Liver Diseases. (Pubmed Central) -  Feb 21, 2024   
    Furthermore, we elucidate the pathophysiological pathways of Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD), Metabolic Associated Steatohepatitis (MASH), and acute liver injuries. A central focus of the review is the exploration of the therapeutic potential of 25HC3S in treating life-threatening conditions, including acetaminophen overdose, endotoxin shock, MASLD, MASH, hepatectomy, and alcoholic hepatitis.
  • ||||||||||  DUR-928 / Durect
    Trial completion, Trial completion date:  DUR-928/AH: DUR-928 in Patients With Alcoholic Hepatitis (clinicaltrials.gov) -  Oct 18, 2023   
    P2,  N=43, Completed, 
    A central focus of the review is the exploration of the therapeutic potential of 25HC3S in treating life-threatening conditions, including acetaminophen overdose, endotoxin shock, MASLD, MASH, hepatectomy, and alcoholic hepatitis. Recruiting --> Completed | Trial completion date: Sep 2024 --> Sep 2023
  • ||||||||||  DUR-928 / Durect, cenicriviroc (TBR-652) / Takeda, AbbVie
    Review, Journal:  Emerging Pharmacotherapies in Alcohol-Associated Hepatitis. (Pubmed Central) -  Jan 18, 2023   
    Their result could potentially make a difference in the clinical course of the disease. DUR-928 and granulocyte colony-stimulating factor had promising results and further trials are ongoing to evaluate their efficacy in the large patient sample.
  • ||||||||||  DUR-928 / Durect
    Trial completion date, Trial primary completion date:  DUR-928/AH: DUR-928 in Patients With Alcoholic Hepatitis (clinicaltrials.gov) -  Nov 9, 2022   
    P2,  N=36, Recruiting, 
    DUR-928 and granulocyte colony-stimulating factor had promising results and further trials are ongoing to evaluate their efficacy in the large patient sample. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
  • ||||||||||  DUR-928 / Durect
    Enrollment open:  DUR-928/AH: DUR-928 in Patients With Alcoholic Hepatitis (clinicaltrials.gov) -  May 4, 2022   
    P2,  N=36, Recruiting, 
    Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023 Not yet recruiting --> Recruiting
  • ||||||||||  DUR-928 / Durect
    [VIRTUAL] Uncovering DUR-928, DNMTs, Alcohol-Associated Hepatitis & NASH () -  Oct 9, 2021 - Abstract #NASHSummitUS2021NASH_Summit_US_41;    
    25HC and 25HC3S are DNMT agonist and antagonist . Synopsis Outlining how DUR-928 acts as an epigenetic Regulator that inhibits DNMTs Learning about hypermethylation and elevated DNMTs in Alcohol-Associated Hepatitis Revealing DUR-928 clinical results and outlining our ongoing program in Alcohol-Associated Hepatitis & NASH
  • ||||||||||  DUR-928 / Durect
    [VIRTUAL] Efficacy Signals Of 4-Week Oral DUR-928 in NASH Subjects (Poster area) -  Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_913;    
    The results suggest that epigenetic regulation of gene expression and their signalling pathways is an attractive approach to treat NASH. Further studyof DUR-928 in subjectswithmetabolic disorders, such asNASH, is warranted.
  • ||||||||||  DUR-928 / Durect
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury (clinicaltrials.gov) -  Mar 21, 2021   
    P2,  N=2, Terminated, 
    As expected, HI resulted in higher exposure due to slower clearance of DUR-928 than MCS. N=80 --> 2 | Trial completion date: Oct 2021 --> Mar 2021 | Recruiting --> Terminated | Trial primary completion date: Sep 2021 --> Mar 2021; low enrollment
  • ||||||||||  DUR-928 / Durect
    [VIRTUAL] SAFETY AND EFFICACY SIGNALS OF 4-WEEK ORAL DUR-928 IN NASH SUBJECTS () -  Oct 11, 2020 - Abstract #AASLD2020AASLD_1693;    
    This study demonstrated that daily oral DUR-928 (50-600mg) for 4 weeks was well tolerated and had an overall improvement in multiple markers, including liver enzymes, liver imaging, and serum lipid profiles, in NASH subjects. The results warrant further study of DUR-928 in subjects with NASH, and suggest that epigenetic modulation of multiple master genes and signaling pathways is an attractive approach to treat NASH.
  • ||||||||||  DUR-928 / Durect
    Trial completion date, Trial initiation date, Trial primary completion date:  DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury (clinicaltrials.gov) -  Sep 29, 2020   
    P2,  N=80, Recruiting, 
    The results warrant further study of DUR-928 in subjects with NASH, and suggest that epigenetic modulation of multiple master genes and signaling pathways is an attractive approach to treat NASH. Trial completion date: Jan 2021 --> Oct 2021 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Dec 2020 --> Sep 2021
  • ||||||||||  DUR-928 / Durect
    Trial initiation date:  DUR-928/AH: DUR-928 in Patients With Alcoholic Hepatitis (clinicaltrials.gov) -  Mar 24, 2020   
    P2,  N=36, Not yet recruiting, 
    However, the drug exposure was not affected by the severity of the disease. Initiation date: Nov 2019 --> Jun 2020
  • ||||||||||  DUR-928 / Durect
    SAFETY AND EFFICACY OF DUR-928: A POTENTIAL NEW THERAPY FOR ACUTE ALCOHOLIC HEPATITIS (Hynes Convention Center, Auditorium) -  Oct 23, 2019 - Abstract #AASLD2019AASLD_3232;    
    One or two doses of the drug significantly reduced serum bilirubin levels at Day 7 after treatment and MELD scores at Day 28. Lille scores of DUR-928 treated patients were significantly better than comparative published historic data1-3.
  • ||||||||||  DUR-928 / Durect
    DUR-928 THERAPY FOR ACUTE ALCOHOLIC HEPATITIS: A PILOT STUDY (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_2469;    
    In this human pilot trial, DUR-928-treated patients had no drug-related SAEs, and the drug was well tolerated. Severity of liver disease did not affect the PK profile.
  • ||||||||||  DUR-928 / Durect
    Trial initiation date:  DUR-928/AH: DUR-928 in Patients With Alcoholic Hepatitis (clinicaltrials.gov) -  Sep 24, 2019   
    P2,  N=36, Not yet recruiting, 
    Severity of liver disease did not affect the PK profile. Initiation date: Jul 2019 --> Nov 2019